ST2 as checkpoint target for colorectal cancer immunotherapy
Kevin Van der Jeught(University of Miami), Xiongbin Lu(The University of Texas MD Anderson Cancer Center)
Cited by 52
Related Papers
Drug resistance and new therapies in colorectal cancer
|World Journal of Gastroenterology|2018|604
PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints
|Genes & Development|2005|383
A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy
|Advanced Science|2023|55